Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 24, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Nancy Wei1, Jamie J O'Byrne2, Miguel Muniz3

  • 1Department of Urology, Mayo Clinic, Rochester, MN.

Clinical Genitourinary Cancer
|June 22, 2026
PubMed
Summary

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Pilot Study of Ex-vivo High Frequency Ultrasound and Core Needle Biopsy to Improve Clinical Tumor Staging of Cancer of the Bladder.

Urology·2026
Same author

Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria.

The Prostate·2026
Same author

Salvage lymph node dissection in oligo-recurrent prostate cancer patients: Mapping patterns of recurrence and factors associated with disease progression.

Urologic oncology·2026
Same author

Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.

BJU international·2026
Same author

Safely Stopping Premedications in Patients Receiving Paclitaxel: A Randomized Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma.

Cancer research communications·2026
Same journal

Trophoblastic-Differentiated Urothelial Carcinoma: Real-World Sequencing and Clinical Implications.

Clinical genitourinary cancer·2026
Same journal

Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

Clinical genitourinary cancer·2026
Same journal

Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.

Clinical genitourinary cancer·2026
Same journal

Beyond the Hazard Ratio: Time-Varying Treatment Effects in Genitourinary Cancer Trials.

Clinical genitourinary cancer·2026
Same journal

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Clinical genitourinary cancer·2026
Same journal

Clinicopathological Predictors of Survival After Radical Nephroureterectomy for UTUC: A Propensity Score-Matched Multicenter Analysis.

Clinical genitourinary cancer·2026
See all related articles
This summary is machine-generated.

Tumor mutation burden (TMB) increases over time and with treatments like radiotherapy in advanced prostate cancer (aPC). This highlights TMB

Area of Science:

  • Oncology
  • Genomics
  • Prostate Cancer Research

Background:

  • Circulating tumor DNA (ctDNA) testing is vital for advanced prostate cancer (aPC) but the longitudinal tumor mutation burden (TMB) is unclear.
  • Current guidelines lack guidance on serial TMB testing.
  • Previous studies suggest modest TMB increases, but systematic analysis of trends and treatment effects is needed.

Purpose of the Study:

  • To evaluate longitudinal TMB changes in aPC.
  • To assess the impact of treatment exposures on TMB.
  • To analyze TMB dynamics in a large real-world cohort.

Main Methods:

  • Retrospective analysis of 714 aPC patients with ctDNA genomic profiling and TMB data.
  • Sequential TMB values mapped to treatment episodes.
Keywords:
Advanced prostate cancerTumor mutation burden dynamicsctDNA testing

Related Experiment Videos

Last Updated: Jun 24, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

  • Linear mixed-effects models used to assess TMB associations with time, age, and therapies.

    • Main Results:

    • TMB significantly increased across treatment episodes (P = .001).
    • Higher TMB associated with increasing age and radiotherapy (RT) exposure.
    • Combination therapies, including RT, showed marked TMB increases.

    Conclusions:

    • Tumor mutation burden (TMB) is dynamic in advanced prostate cancer (aPC), increasing over time and with specific treatments.
    • TMB should be interpreted in context, not solely as a threshold for immunotherapy initiation.